Cardiology

Heart 01 Jan 2013

SMOOTH – Blood Pressure Control in Diabetic/Obese Patients

The primary objective of the SMOOTH study was to demonstrate that, when combined with hydrochlorothiazide (12.5 mg), telmisartan (80 mg) is at least as effective and possibly superior to valsartan (160 mg) in lowering systolic and diastolic BP during the last 6 hours of the 24-hour dosing interval (i.e., the…
Glycemic Load, Weight Loss and Cardiovascular Disease Risk
Heart 01 Jan 2013

Glycemic Load, Weight Loss and Cardiovascular Disease Risk

To investigate the hypothesis that reducing the glycemic load of the diet will improve changes in body composition and cardio-vascular risk factors. The study compares a conventional reduced-fat, high carbohydrate diet with 3 means of reducing glycemic load: changing the carbohydrates to low-GI choices, replacing some of the carbohydrate with…
Effect of Abdominal Obesity on Lipoprotein Metabolism
Heart 01 Jan 2013

Effect of Abdominal Obesity on Lipoprotein Metabolism

Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. Hypothesis: Reduction in abdominal fat mass by weight loss decreases apoB concentration and raises HDL-cholesterol chiefly by increasing LDL-apoB fractional catabolic rate (FCR), as well as decreasing HDL apoA-I, respectively.
High Density Lipoprotein Turnover
Blood 01 Jan 2013

High Density Lipoprotein Turnover

The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period. Official Title A Randomized, Double-Blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in…
Panic Disorder and Cardiac Risk
Heart 01 Jan 2013

Panic Disorder and Cardiac Risk

The reason for increased cardiac mortality in panic disorder has not been precisely identified, but possibly is due to chronic activation of the cardiac stimulant (sympathetic) nerves, which may predispose the individual with panic disorder to disorders of cardiac rhythm and coronary artery spasm. The uniqueness of this study lies…
Study to Assess If Internet-Based Tailored Advice Could Modify Behaviour to Improve Health
Blood 01 Jan 2013

Study to Assess If Internet-Based Tailored Advice Could Modify Behaviour to Improve Health

The purpose of this trial is to find out if a special website might help people discover if they have high cholesterol and then enable them to manage their cholesterol more appropriately. The primary aim of this trial is to determine the effects on consumers’ use of cholesterol lowering therapy…
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
Blood 01 Jan 2013

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

This study will evaluate the lipid-lowering effect and safety of colesevelam therapy administered to heterozygous familial pediatric patients 10 through 17 years of age who are on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin, simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy. Official Title…
Telmisartan vs. Losartan for Improvement of Renal Function in Hypertensive Diabetic Patients With Overt Nephropathy.
Heart 01 Jan 2013

Telmisartan vs. Losartan for Improvement of Renal Function in Hypertensive Diabetic Patients With Overt Nephropathy.

A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease. Losartan (COZAAR), is one such drug. The purpose of this research study…
Heart 01 Jan 2013

Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease

We aim to perform a prospective, randomised study assessing the impact of alendronate on cardiovascular and bone mineral parameters. This will be a single-centre study involving subjects with CKD Stage 3 (those patients with GFR between 30 and 59ml/min). Arterial stiffness (by pulse wave analysis and pulse wave velocity) and…